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Abstract
Background: Medications used to augment lactation increase prolactin secretion but can have
intolerable side effects. We examined the biological activity of recombinant human prolactin (r-
hPRL) as preliminary data for its use to augment lactation.
Methods: Healthy, non-postpartum women (n = 21) with regular menstrual cycles underwent a
seven day randomized, double-blind, placebo-controlled trial of r-hPRL. Expressible galactorrhea,
markers of bone turnover, calcium homeostasis and gonadal function were measured and side
effects recorded.
Results: Prolactin levels increased during r-hPRL administration (20.0 ± 2.8 to 231.7 ± 48.9 µg/L
at 6 hours; p < 0.05). Five of nine participants who received r-hPRL developed expressible
galactorrhea (p < 0.001). Urinary deoxypyridinoline decreased and bone specific alkaline
phosphatase increased in r-hPRL and placebo groups. Menstrual cycle lengths were not altered and
side effects were similar between r-hPRL and placebo groups.
Conclusion:  In summary, r-hPRL can cause expressible galactorrhea. Seven days of r-hPRL
administration does not adversely affect bone turnover or menstrual cyclicity. Thus, r-hPRL may
be a viable option for short-term lactation augmentation.
Trial registration: Clinical Trials.gov NCT00438490
Background
Breastfeeding has many important health implications for
mothers and infants [1]. However, there can be obstacles
to breastfeeding even in the most motivated women. The
prevalence of lactation insufficiency may be as high as
15% in newly lactating women [2]. The rate of lactation
insufficiency is even higher in mothers of premature
infants who must pump breast milk to feed their babies in
neonatal intensive care units [3]. The causes of lactation
insufficiency are multifactorial and include poor sucking,
structural breast abnormalities and infrequent feedings by
the infant. They also include poor milk production and
poor letdown [2].
A subset of mothers with poor milk production has insuf-
ficient prolactin secretion, although the absolute prolac-
tin levels required for adequate lactation and the number
of women affected is unknown. Prolactin is critical to
Published: 24 July 2007
International Breastfeeding Journal 2007, 2:10 doi:10.1186/1746-4358-2-10
Received: 9 February 2007
Accepted: 24 July 2007
This article is available from: http://www.internationalbreastfeedingjournal.com/content/2/1/10
© 2007 Page-Wilson et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.International Breastfeeding Journal 2007, 2:10 http://www.internationalbreastfeedingjournal.com/content/2/1/
Page 2 of 8
(page number not for citation purposes)
breast milk production based on absence of lactation in
the absence of prolactin [4] and evidence that bromocrip-
tine abolishes lactation at many stages, even late postpar-
tum when basal prolactin levels have reached the normal
range [5]. The majority of studies demonstrate a relation-
ship between prolactin levels and milk volume [6-10],
with low basal and suckling stimulated prolactin concen-
trations in women with the poorest lactation [9]. Agents
that increase endogenous prolactin, such as metoclopra-
mide and domperidone, have been used in a 7–10 day
course to increase breast milk supply in mothers with lac-
tation insufficiency [11-14]. However, these medications
can be associated with side effects such as drowsiness and
depression and alternative therapies are needed
[12,15,16]. Recombinant human prolactin (r-hPRL) is a
potentially new therapy that is available for investiga-
tional use; however, its biological activity and side effect
profile have not been examined.
As a consequence of the large calcium requirements of lac-
tation, markers of bone formation and resorption are
increased [17] and bone density declines at trabecular and
cortical sites [18]. Women with pathological hyperprol-
actinemia exhibit reduced radial and vertebral body bone
mineral density compared to controls [19]. It has been
suggested that the decrease in bone density observed dur-
ing lactation and in hyperprolactinemic women is largely
due to the hypoestrogenemia that can accompany hyper-
prolactinemia [20,21]. However, the bone loss during lac-
tation exceeds that in women with GnRH agonist-induced
hypoestrogenemia [22]. Similarly, women with patholog-
ical hyperprolactinemia and amenorrhea exhibit lower
radial bone mineral content than amenorrheic women
with normal prolactin levels [23]. Further, prolactin levels
correlate inversely with bone density and markers of bone
formation and directly with markers of bone resorption
[24]. Finally, prolactin receptors have been identified on
osteoblasts [25]. Taken together, these data suggest that
prolactin may have a direct effect on bone turnover in
addition to effects mediated by estrogen suppression.
These potential prolactin effects on bone must be identi-
fied in estrogen replete women to isolate effects related
directly to prolactin and not the concomitant estrogen
deficiency in hyperprolactinemic states.
Lactation is also associated with amenorrhea. The etiology
of lactational amenorrhea may include the suckling stim-
ulus, energy deficit related to the increased catabolic
demands of lactation, increased sensitivity to estradiol
feedback and elevated prolactin levels [26]. We have pre-
viously shown that prolactin has direct effects on GnRH
secretion in the absence of changes in menstrual cycle
length when given for a seven day course [27]. The
absence of a direct effect of r-hPRL on menstrual cycle
length needs confirmation.
The goal of this study was to determine whether r-hPRL
was biologically active and to examine potential side
effects from the use of r-hPRL on bone turnover and men-
strual cyclicity, since prolactin may have direct effects on
these parameters as outlined above. We chose not to study
lactating women for these pilot studies because the enor-
mous changes in bone turnover and the hypoestrogenic
state that accompany lactation could not be separated
from the effect of prolactin administration itself. There-
fore, we treated regularly cycling, estrogen replete, non-
postpartum women with prolactin at doses targeted to
achieve prolactin levels during lactation [9,28-30]. Using
estrogen replete, non-lactating women allowed us to iso-
late the direct effects of r-hPRL from effects related to the
postpartum state and the concomitant estrogen defi-
ciency.
Methods
A total of twenty-one healthy women aged 21 – 38 years
(28.4 ± 5.4 years, mean ± SD) were studied during the
years 2002 and 2003 in a randomized, double blind, pla-
cebo-controlled trial of recombinant human prolactin
administration (r-hPRL; Genzyme Corporation, Cam-
bridge, MA [31]). All participants had a history of regular
25 – 35 day menstrual cycles with ovulation documented
by a luteal phase progesterone level. All participants had
normal prolactin and thyroid stimulating hormone (TSH)
levels, renal function, hemoglobin ≥ 110 g/L, body mass
index (BMI) 17.5 – 30.4 kg/m2, and no evidence of andro-
gen excess, expressible or spontaneous galactorrhea or
breast masses. Participants were non-smokers, had no his-
tory of osteoporosis, alcoholism or medical problems,
and used no medications known to affect bone turnover
and no hormonal medications for at least three months.
The study protocol was approved by the Massachusetts
General Hospital (MGH) Human Research Committee
and all participants gave written informed consent before
participation.
Participants were studied in the follicular phase of the
menstrual cycle, starting between days 1 and 8 after men-
ses. Before the first injection, participants underwent a
breast exam to document the absence of expressible galac-
torrhea and collected a 24 hour urine sample for calcium,
creatinine, phosphorus, deoxypyridinoline and N-tel-
opeptide. At the completion of the urine collection, par-
ticipants had blood drawn for calcium, phosphorus,
parathyroid hormone (PTH), parathyroid related protein
(PTH-rP), 1,25-(OH)2 vitamin D, albumin, bone specific
alkaline phosphatase, estradiol, luteinizing hormone
(LH) and follicle stimulating hormone (FSH). Partici-
pants also kept a 48-hour food record, which was used to
match calcium, phosphorus, sodium and protein con-
sumed during the 48-hour period surrounding the final r-
hPRL injection.International Breastfeeding Journal 2007, 2:10 http://www.internationalbreastfeedingjournal.com/content/2/1/
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The participants were randomized by the research phar-
macy using a random number generator to receive a sub-
cutaneous (SC) r-hPRL or placebo injection for seven
days. To achieve prolactin levels in the range of those
measured in postpartum women, i.e. 100–250 µg/L [9,28-
30], the first subject was treated with 300 µg/kg r-hPRL
based on pharmacokinetic data from the manufacturer
(Genzyme Corporation). However, prolactin levels in the
first subject reached 900.6 µg/L using this protocol and
the dose was decreased to 60 µg/kg r-hPRL for subsequent
participants. The data from the first subject was not
included in the mean prolactin level calculations. Blood
was drawn for prolactin levels at baseline and 2, 4, and 6
hours after the injection and vital signs were monitored
during the 3 hours immediately following the injection. A
transvaginal or transabdominal ultrasound was per-
formed and the maximum diameter of all follicles ≥ 10
mm was recorded.
Participants either returned daily to the GCRC or self-
administered 60 µg/kg r-hPRL or placebo injections for six
additional days. Blood was drawn for estradiol, LH and
FSH levels before each daily injection. On the day before
the final injection, participants began a second 48-hour
food record to determine if dietary components matched
those consumed in the first 48 hours of the study.
On the day of the final r-hPRL or placebo injection, blood
was drawn as above and participants collected a second
24-hour urine sample. The transvaginal or transabdomi-
nal ultrasound was repeated to assess follicle growth.
Twenty-four hours after the final r-hPRL or placebo injec-
tion, blood samples were drawn as on the day before the
first injection and breasts were examined for the presence
of expressible galactorrhea by palpation. Participants were
asked to describe any side effects and adverse events were
recorded. Participants returned 2–3 weeks later for a urine
pregnancy test and an assessment of menstrual cycle
length.
Assays
Deoxypyridinoline (Dpd; Pyrilinks-D, Quidel, San Diego,
CA), N-telopeptide (NTX; Osteomark, Ostex Interna-
tional, Inc., Seattle, WA), and bone specific alkaline phos-
phatase (BSAP; Alkphase-B, Quidel, San Diego, CA) were
measured using enzyme-linked immunosorbent assays
(ELISAs) according to the manufacturers' directions. For
deoxypyridinoline the intra-assay coefficients of variation
(CVs) were 8.5, 5.6, and 4.9% at concentrations of 10.6,
72.1, and 135 nM Dpd/mM creatinine (Cr), respectively,
and the inter-assay CVs were 7.6 and 4.2% at concentra-
tions of 18.0 and 99.9 nM Dpd/mM Cr. For N-telopeptide
the intra-assay CVs were 8.6, 5.0, and 5.7% at concentra-
tions of 155, 818, and 1630 nM bone collagen equiva-
lents (BCE)/mM Cr, and the inter-assay CVs were 12.5 and
10.2% at concentrations of 407 and 1420 nM BCE/mM
Cr. For BSAP, the intra-assay CVs were 3.3, 3.5, and 2.9%
at concentrations of 12.3, 58.2, 96.7 U/L, and the inter-
assay CVs were 3.7 and 6.5% at concentrations of 13.1
and 65.0 U/L. Serum prolactin, LH, FSH, and estradiol
were measured using a 2-site monoclonal non-isotopic
system according to the manufacturer's directions
(Axsym, Abbott Laboratories, Abbott Park, IL). LH and
FSH levels are expressed in IU per liter as equivalents of
the Second International Reference Preparation 71/223 of
human menopausal gonadotropins. The interassay CVs
for the LH assay were 5.3, 5.5 and 7.4% at concentrations
of 5.6, 26.2 and 69.0 IU/L. The interassay CVs for the FSH
assay were 6.9, 7.1 and 6.3% at concentrations of 4.3, 35.4
and 79.5 IU/L. The CVs for the estradiol assay were 9.2,
5.4 and 9.6% at estradiol concentrations of 312, 1101,
2570 pmol/L. The CVs for the prolactin assay were 4.6, 4.5
and 5.2% for prolactin concentrations of 8, 20 and 40 µg/
L. Intact PTH was measured using a two-site chemilumi-
nescence immunoassay (Nichols Institute Diagnostics,
San Clemente, CA). The sensitivity of the assay was 5 pg/
mL and the interassay CVs were less than 5.5 and 6% at
concentrations of 21.7 and 143.5 ng/L. PTHrP (1–86) was
measured using a two-site immunoradiometric assay
(Diagnostic Systems Laboratories Inc., Webster, Tx, USA).
The sensitivity of the assay was 0.3 pM and the intra- and
interassay CVs were 4.8% and 13.6%. 1,25-(OH)2 vitamin
D was measured by radioimmunoassay (RIA; DiaSorin,
Inc., Stillwater, MN). The interassay CVs were 14.6, 11.1
and 11.2% for quality control sera at low, medium and
high concentrations. For all measurements, all samples
for a given individual were run in the same assay.
Data Analysis
Studying a total of 21 participants was expected to yield at
least 8 participants who received r-hPRL, resulting in a
greater than 90% chance of detecting galactorrhea at a 2-
sided, 5% significance level if the rate of spontaneous or
expressible galactorrhea in women with regular menstrual
cycles is 1% [32]. Twenty-one participants also resulted in
an 80% probability that the study would detect a signifi-
cant difference in markers of bone turnover at a 2-sided,
5% significance level.
All data were normally distributed. A z -test was used to
determine whether the rate of expressible galactorrhea
exceeded 1%, the incidence in regularly cycling women
[32]. Prolactin, gonadotropins, estradiol concentrations,
markers of bone formation and resorption, calcium,
phosphorus, albumin, PTH, PTHrP, 1,25-(OH)2 vitamin
D and follicle size were analyzed using 2 way repeated
measures ANOVA during r-hPRL or placebo administra-
tion and significant differences were further analyzed
using a Tukey post hoc test. Calcium, phosphorus,
sodium, vitamin D and macronutrient intake were com-International Breastfeeding Journal 2007, 2:10 http://www.internationalbreastfeedingjournal.com/content/2/1/
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pared before and after r-hPRL or placebo administration
using paired t-tests. Results are expressed as mean ± SEM
unless otherwise indicated. A p value of < 0.05 was consid-
ered significant.
Results
In the r-hPRL treated group, prolactin levels increased
from 16.6 ± 2.4 µg/L to a peak of 164.2 ± 20.3 µg/L 4
hours after the first 60 µg/kg r-hPRL injection (Figure 1).
The prolactin level was unchanged at baseline before the
seventh r-hPRL injection (16.9 ± 1.5 µg/L) and increased
to a peak of 141.9 ± 10.9 µg/L four hours after the final r-
hPRL injection. In the placebo group, baseline prolactin
levels (15.0 ± 1.5 vs. 15.3 ± 2.0 µg/L; before and on the
seventh day of placebo injections, respectively; p = NS)
and prolactin levels over 6 hours (12.8 ± 1.8 vs. 19.1 ± 4.9
µg/L at 6 hours; p = NS; Figure 1) did not change after
seven days of placebo injections, as expected.
None of the participants had expressible galactorrhea at
baseline. During the seven days of r-hPRL administration,
five of the nine participants experienced several drops of
expressible galactorrhea (p < 0.001), and two of those five
participants experienced breast tenderness or fullness. The
breast secretions were milky white in color, bilateral and
had no evidence of blood or abnormal coloration. Of the
five participants who experienced expressible galactor-
rhea, two had been pregnant and one delivered a child 5
years before participating in the study. Of the four partic-
ipants who did not develop expressible galactorrhea, three
had been pregnant and two had delivered children 3 years
and 7 years before participating in the study. There was no
difference in age in the participants who experienced
galactorrhea compared to those who had not (28.3 ± 5.1
vs. 29.8 ± 3.3 years, mean ± SD; p = 0.6; galactorrhea vs.
no galactorrhea, respectively). None of the participants in
the placebo group developed spontaneous or expressible
galactorrhea. One subject receiving r-hPRL noted mild
fatigue and moodiness. One subject had a tender lymph
node in the groin area, thought to be unrelated to the r-
hPRL. There were no other side effects in the r-hPRL treat-
ment group. In the placebo group, side effects included
diarrhea, nausea (n = 2), headache (n = 3), fatigue, fever
and bruising at the blood drawing site.
Urinary deoxypyridinoline concentrations tended to
decrease in the r-hPRL group (Table 1; p = 0.07) and did
decrease in the group as a whole (8.2 ± 1.0 vs. 7.1 ± 0.8
nM Dpd/mM Cr; p < 0.05), but there were no significant
changes in the placebo group. There were no changes in
urinary N-telopeptide after seven days of r-hPRL or pla-
cebo treatment. Bone specific alkaline phosphatase
increased during seven days of placebo treatment (p <
0.01) and in the group as a whole (16.1 ± 1.2 U/L vs. 17.7
± 1.3 U/L; p < 0.01), but not during r-hPRL administra-
tion.
Serum calcium concentrations increased significantly dur-
ing seven days of r-hPRL and placebo administration,
however, there was no significant effect of treatment on
this increase (p = 0.74) and the change in calcium concen-
tration was not different when corrected for albumin con-
centration (Corrected [Ca] = Measured total [Ca] + (0.8 ×
(4.5 - [alb])); Table 1). There were no changes in serum
phosphorus, PTH, PTHrP, 1,25-(OH)2 vitamin D concen-
trations or in the urinary Ca/Cr and urinary phosphorus/
Cr ratios after seven days of r-hPRL and placebo treatment
(Table 1). There were also no changes in energy, macronu-
trient, calcium, phosphorus or sodium intake or in the Cr
clearance in the 24 hours before r-hPRL or placebo injec-
tions began and in the final 48 hours of the injections
(Table 2).
Serum estradiol levels (217.3 ± 29.8 vs. 634.3 ± 175.1 and
186.1 ± 20.6 vs. 466.6 ± 72.4 pmol/L; before and after 7
days of placebo and r-hPRL, respectively; p < 0.05 for
both) and follicle size (10.2 ± 0.8 vs. 15.9 ± 2.0 and 9.7 ±
0.8 vs. 15.6 ± 1.4 mm; p < 0.05 for both) increased after 7
days of placebo and r-hPRL treatment, as expected during
the follicular phase of the menstrual cycle, and there was
no difference between the two groups (Figure 2). There
were no differences in LH and FSH between groups. There
was no evidence of spotting or irregular menstrual bleed-
ing during or after the study. Menstrual cycle length was
similar during r-hPRL and placebo treatment (28.8 ± 1.0
vs. 30.1 ± 1.1 days; placebo vs. r-hPRL; p = 0.09).
Prolactin levels after r-hPRL or placebo injections Figure 1
Prolactin levels after r-hPRL or placebo injections. 
Prolactin levels (mean ± SE) after administration of 60 µg/kg 
recombinant human prolactin (solid lines) or placebo (dotted 
lines) on the first (closed circles) and 7th day of injections 
(open squares), over 6 hours. * designates significant differ-
ences in r-hPRL and placebo on the same day at p < 0.05.
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Discussion
Based on the overwhelming advantage of breast milk as
an infant's source of nutrition coupled with a subset of
women who have lactation insufficiency related to prolac-
tin deficiency, additional medication to augment lacta-
tion without side effects is needed [3]. This study
demonstrates the biological activity of r-hPRL in eliciting
treatment-induced, expressible galactorrhea. In addition,
r-hPRL induced no adverse changes in bone turnover
when isolated from the hypoestrogenemia that occurs in
physiological states of hyperprolactinemia [20,33,34].
There were also no changes in estradiol or menstrual cycle
length in the current study or in our previous study in
which r-hPRL was administered twice daily [27]. Finally,
there were no significant adverse side effects reported.
These data suggest that short-term use of recombinant
human prolactin can produce expressible galactorrhea
and is not detrimental to bone turnover or menstrual
cyclicity.
In the current study, r-hPRL administration once daily for
seven days was adequate to induce expressible galactor-
rhea, a time frame chosen based on studies of other lacta-
tion induction agents [11-14]. In a previous study in
which r-hPRL was administered every 12 hours for seven
days to examine its effect on GnRH secretion [27], four of
six participants developed expressible galactorrhea, how-
ever, this study was not powered to examine efficacy. The
pattern of hyperprolactinemia after r-hPRL administra-
tion does not perfectly replicate physiological or patho-
logical hyperprolactinemia, however, it should be similar
to the prolactin increase induced by metoclopramide.
Studies are now ongoing to determine whether r-hPRL
will augment milk production in postpartum mothers
with lactation insufficiency and to determine the mini-
mum dosing interval required. Further studies will deter-
mine whether r-hPRL can induce lactation in mothers
with prolactin deficiency and absence of lactotrophs, such
as women with a history of Sheehan's syndrome, and in
Table 1: Markers of bone turnover and calcium homeostasis during r-hPRL or placebo treatment
Placebo r-hPRL
Before treatment After treatment Before treatment After treatment
Deoxypyridinoline (nM/mM) 7.2 ± 0.6 6.9 ± 0.7 9.5 ± 2.1 7.4 ± 1.8
N-telopeptide (nM/mM Cr) 45.3 ± 4.6 42.3 ± 5.6 35.6 ± 4.0 31.9 ± 4.1
Bone specific alk phos (U/L) 15.4 ± 1.3 17.5 ± 1.5* 17.0 ± 2.2 18.1 ± 2.5
Calcium (mmol/L) 2.3 ± 0.03 2.4 ± 0.03* 2.3 ± 0.03 2.4 ± 0.03*
Albumin (g/L) 40 ± 1 43 ± 1* 40 ± 1 42 ± 1
Corrected calcium (mmol/L) 2.4 ± 0.03 2.4 ± 0.03 2.4 ± 0.03 2.5 ± 0.05
Phosphorus (mmol/L) 1.2 ± 0.03 1.1 ± 0.03 1.0 ± 0.06 1.1 ± 0.06
PTH (ng/L) 45.7 ± 4.4 47.6 ± 4.5 46.8 ± 5.9 38.8 ± 6.2
PTH-rP (pmol/L) 0.33 ± 0.02 0.35 ± 0.04 0.30 ± 0.00 0.37 ± 0.05
1,25-(OH)2 Vit D (pmol/L) 102.2 ± 7.0 102.2 ± 6.7 115.4 ± 17.5 117.6 ± 25.2
Urinary Ca/Cr 0.11 ± 0.02 0.11 ± 0.02 0.10 ± 0.02 0.15 ± 0.02
Urinary Phos/Cr 0.61 ± 0.07 0.61 ± 0.08 0.60 ± 0.07 0.59 ± 0.05
All results: mean ± SE
* p < 0.05 within a group as indicated by the Tukey post hoc test.
Table 2: Average daily energy, macronutrient, Vitamin D and mineral intake during r-hPRL or placebo administration
Placebo r-hPRL
Before treatment After treatment Before treatment After treatment
Energy (kcal) 1963 ± 164 1929 ± 164 1670 ± 190 1606 ± 244
Fat (g) 65. ± 8.4 66.9 ± 6.7 58.3 ± 8.1 55.8 ± 11.4
Protein (g) 67.5 ± 7.5 71.8 ± 7.5 63.8 ± 7.1 62.9 ± 9.9
Carbohydrate (g) 283 ± 23 267 ± 25 225 ± 27 206 ± 33
Vitamin D (µg) 3.7 ± 0.9 4.1 ± 0.9 5.9 ± 3.8 2.9 ± 0.8
Calcium (mg) 849 ± 92 749 ± 113 1019 ± 162 1054 ± 210
Phosphorus (mg) 1166 ± 123 1131 ± 135 1093 ± 106 1029 ± 128
Sodium (mg) 3460 ± 436 3823 ± 497 2505 ± 222 2517 ± 328
All results: mean ± SEInternational Breastfeeding Journal 2007, 2:10 http://www.internationalbreastfeedingjournal.com/content/2/1/
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adoptive mothers. Finally, although previous studies have
suggested that the composition of milk in nonpuerperal
women with induced lactation or hyperprolactinemia
from medication, prolactinomas or hypothyroidism was
similar to that of transitional or mature milk in composi-
tion [35-37], the milk composition will need to be exam-
ined in mothers who desire to lactate using r-hPRL long-
term.
It is encouraging that r-hPRL did not increase markers of
bone resorption or decrease bone specific alkaline phos-
phatase, a marker of bone formation, during short-term
use for its potential development as a galactagogue. Nev-
ertheless it is surprising. From the early follicular phase to
the early luteal phase in non-lactating women markers of
bone formation such as osteocalcin and bone specific
alkaline phosphatase increase, as demonstrated in the cur-
rent study and others [38-40], presumably in response to
the increase in estradiol and possibly androgen levels.
Markers of bone resorption such as urinary deoxypyridin-
oline, pyridinoline and N-telopeptide have been demon-
strated to decrease [38], remain unchanged [41] or
increase [40,41] from the early follicular phase through
the early luteal phase of the menstrual cycle. In the current
study, urinary deoxypyridinoline decreased across the fol-
licular phase in the whole group of women. The findings
in the current study are strengthened by the matched
macro- and micronutrient intake at the time of the two
evaluations. There was no independent effect of r-hPRL
treatment on markers of bone formation or resorption,
although there was a trend toward a decrease in urinary
deoxypyridinoline in r-hPRL treated participants. Of note,
short-term hyperprolactinemia did not disrupt the nor-
mal estradiol increase across the follicular phase of the
menstrual cycle in our current or previous study using
twice daily r-hPRL dosing, nor did a 12 hour r-hPRL infu-
sion cause fluctuations in estradiol concentration [27].
Taken together, the absence of a change in bone forma-
tion markers and the trend toward a decrease in markers
of bone resorption with short-term r-hPRL administration
suggest that the increased bone resorption and formation
observed in lactation [17] and the increased resorption
and decreased formation in patients with hyperprol-
actinemia from prolactinomas [42] are associated with
estrogen deficiency and changes in PTHrP that accompany
these physiological states. Thus, the physiological effects
of lactation would be expected to account for any changes
in bone turnover during long-term r-hPRL administra-
tion.
The current study also examined the hormones control-
ling calcium homeostasis and determined that short-term
hyperprolactinemia does not affect endogenous calcium
concentrations. R-hPRL treatment did not decrease uri-
nary calcium excretion, as had been demonstrated in ani-
mal models [43]. There was no increase in 1,25 (OH)2
vitamin D in women treated with r-hPRL for 7 days, sug-
gesting that prolactin does not regulate 1-hydroxylation of
vitamin D in women, consistent with previous observa-
tional studies [44-46]. There was also no increase in
PTHrP during r-hPRL treatment, an observation that is
surprising in light of the association between PTHrP and
prolactin in lactating women and women with hyperpro-
lactinemia [20,33,34] and interventional studies in ani-
mals [47,48]. Data demonstrating stimulation of PTH-rP
in the suckled, but not the contralateral mammary gland
provides evidence that a locally produced factor stimu-
lates PTH-rP [49] and there is increasing evidence that
extracellular calcium regulates PTHrP production via the
Reproductive hormone concentrations during r-hPRL or pla- cebo injections Figure 2
Reproductive hormone concentrations during r-
hPRL or placebo injections. LH, FSH and estradiol (E2) 
concentrations (mean ± SE) in normal women during 7 days 
of treatment with placebo (n = 12; black bars) and r-hPRL (n 
= 9; white bars) in the early (EFP), mid (MFP) and late follicu-
lar phase (LFP). There were no differences in hormone con-
centrations at any cycle stage between the two groups.
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calcium receptor in the lactating breast [50]. Nevertheless,
it is possible that the duration of prolactin exposure in the
current study was insufficient to increase PTHrP. Although
the duration of hyperprolactinemia was sufficient to pro-
duce expressible galactorrhea in a majority of the partici-
pants, breast milk PTHrP levels increase with increasing
duration of lactation [51-53] and women with longstand-
ing prolactinomas and lactating women [20,33,34] are
exposed to elevated prolactin levels for months, not days.
Further, the volume of breast tissue may determine serum
PTHrP levels [54]. Finally, a transient change in PTHrP
during r-hPRL administration was not ruled out, although
there was also no change in 24 hour urine concentrations
of calcium and phosphorus, which would be expected to
change with any transient change in PTHrP.
The current data also confirm and expand previous find-
ings examining calcium changes across the menstrual
cycle. When calcium was corrected for albumin, there was
no change across the follicular phase, similar to previous
studies [38,39,55]. There were also no changes in urinary
calcium or phosphorus excretion, PTHrP or 1,25 (OH)2
vitamin D across the follicular phase in the current study
or others [39]. Although PTH changes across the men-
strual cycle have been more variable, demonstrating no
change [39] a peak in the early luteal phase [38] or a
decrease in the luteal phase [40], the current data demon-
strate no change. Taken together, the data confirm and
expand previous findings demonstrating that measure-
ments of calcium homeostasis are not affected by the hor-
monal changes in the menstrual cycle.
Conclusion
The data demonstrate that r-hPRL is biologically active,
producing expressible galactorrhea in the majority of
treated women with minimal side effects. Further, this
randomized, placebo-controlled trial of r-hPRL adminis-
tration for seven days isolated the effect of prolactin on
bone from the effect of hypoestrogenemia and changes in
the hormones regulating calcium homeostasis that can
accompany hyperprolactinemia and lactation. The data
demonstrate that r-hPRL does not have a detrimental
effect on the markers of bone turnover. Further, short-
term r-hPRL administration had no effect on estradiol or
menstrual cycle length. Taken together, r-hPRL appears to
have no direct detrimental effect on bone or menstrual
cycle length during the short-term administration that
would be used to augment lactation. Further studies are
ongoing to examine short and long-term use of r-hPRL in
lactating mothers.
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